Non Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 1st Line

EGFR Wild-type; ALK-; RS01 -

LUN0092
Phase Ib PDR001 in Combination w/ Platinum-Doublet Chemotherapy in PD-L1 Metastatic NSCLC

PI: Wakelee
Novartis Pharmaceuticals

LUN0109
Phase III Pembrolizumab + Platinum-Based Doublet Chemo +/- Canakinumab in Non-Squamous & Squamous NSCLC

PI: Neal
Sponsor: Pending

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu